Home
ABBOTINDIA.NS

Abbott India Limited

NSEHealthcare
₹26,090.00
+1.42%+₹365.00 today
₹0.00₹0.00
Ask Warren
Open
₹0.00
Prev close
₹25,725.00
Day range
₹0 – ₹0
52W range
₹25,150 – ₹35,675
Volume
21.1K
Avg vol (20D)
10.1K
Mkt cap
₹55,025.07Cr
P/E TTM
35.4×

Trade Abbott India Limited with Artha

Sign in to place orders, set alerts, and sync your watchlist.

Sign in to trade

Company Metrics

Revenue (ttm)₹6929.05 Cr
Net Income (ttm)₹0.00
Shares Out2.12 Cr
EPS (ttm)
Forward PE
Dividend
Ex-Dividend DateInvalid Date

Trading Metrics

Beta0.02

About ABBOTINDIA.NS

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, pain management, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.

IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees0
Stock ExchangeNSE
Ticker SymbolABBOTINDIA.NS
ABBOTINDIA.NS · NSE
Financial Performance

In 2026, Abbott India Limited's revenue was ₹6929.05 Cr, an increase of +6.50% compared to the previous year. Earnings were ₹0.00, an increase of +7.60%.

Revenue (2026)
₹6929.05 Cr
+6.50% YoY
Earnings (2026)
₹0.00
+7.60% YoY
Year-over-Year Growth
Revenue
+6.50%
Earnings
+7.60%

News

Save watchlists across devicesSet price alerts that buzz your phoneConnect Zerodha for one-tap trades
Create free account

We use analytics cookies to understand how you use Artha and improve your experience. No data is sold to third parties.